GQ1007

P1, N=200, Not yet recruiting, GeneQuantum Healthcare (Suzhou) Co., Ltd.

HER2 is a proven target for breast cancer, gastric cancer and other solid tumours GQ1007 is HER2 AIAC that has been developed using GeneQuantum’s unique iLDC bioconjugation platform, leading excellent druggability and linker stability Review how GQ1007 demonstrates robust in vitro and in vivo anti-tumour activities in multiple preclinical models Evaluate how GQ1007 has the potential to become an important therapeutic option for the HER2+ patients who have progressed on current standard therapies, and a combo opportunity with PD1 therapy

HER2 is a proven target for breast cancer, gastric cancer and other solid tumors GQ1007 is HER2 AIAC that has been developed using GeneQuantum’s unique iLDC bioconjugation platform, leading to excellent druggability and linker stability GQ1007 demonstrates robust in vitro and in vivo anti-tumor activities in multiple preclinical models Discuss GQ1007’s potential to become an important therapeutic option for the HER2+ patients who have progressed on current standard therapies, and a combo opportunity with PD1 therapy Lunch